Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7047662
Reference Type
Journal Article
Title
Prescription pattern of fixed dose drug combination in tertiary care hospital: An evaluation study
Author(s)
Eesha, BR; Shanbhag, T; Adiga, MGS; Shenoy, S; ,
Year
2009
Is Peer Reviewed?
1
Journal
Biomedical Research
ISSN:
0970-938X
EISSN:
0976-1683
Publisher
ALLIED ACAD
Location
LONDON
Page Numbers
176-179
DOI
10.4103/0970-938X.54837
Web of Science Id
WOS:000269215400006
Abstract
The fixed dose combination (FDC) therapy varies among countries. The available combination drugs in the market include both rational and irrational ones. The use of irrational fixed dose combination has a great impact on consumers, society and the nation. Since a few studies on prescribing patterns of fixed dose combination are available in literature, there is need for such a study. In this prospective study, carried out in a tertiary care teaching private hospital, one thousand prescriptions from the hospital pharmacy were collected, classified according to anatomic therapeutic and chemical (ATC) classification. The fixed drug combination used was compared with the essential drug list of World Health Organization (WHO) and other countries. In one thousand prescriptions, 3151 drugs were prescribed, of which, 960 were fixed dose combination drugs. Among those, the anti-infective agents for systemic use (17.5) and drugs affecting the central nervous system (17.08), cardiovascular system (15.41) and alimentary system (11.14) mainly contributed to the fixed dose combinations. The highest percentage of FDCs was seen among the nervous system (36.6), anti-infective (33.67), anti-neoplastic (31), respiratory system (31) and various drugs (35.90) category which were more than the average percentage of fixed dose combination drug use (30.47). Majority of the FDCs prescribed (73.25) were not approved in the WHO essential drug list. There is a significant burden of these combinations on consumers, physicians and policy makers which needs to be handled with care.
Tags
•
PFAS Universe
Data Source
Web of Science
Perflunafene
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity